RegenETP Stock Forecast for 2023 - 2025 - 2030

Updated on 05/11/2024

Stock Rating
0
Price Target
$0.00
Consensus
-
Upside
1042.86%
Analysts
0
Stock Rating
0
Upside
1042.86%
Analysts
0
Price Target
$0.00
-

RegenETP Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, Price for RegenETP has grown by 100.00%, going from $0.00 to $0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $0.00 – an increase of 100.00%. Over the next six years, experts anticipate that Fair Value growth for RegenETP will be 100.00%.

2025 Fair Value Forecast
$0.00
2026 Fair Value Forecast
$0.00
2027 Fair Value Forecast
$0.00
2028 Fair Value Forecast
$0.00
2029 Fair Value Forecast
$0.00
2030 Fair Value Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
VCEL Stock Forecast Vericel Buy 8
$48.10 Buy/Sell $42.58 16.42%
IART Stock Forecast Integra LifeSciences Holdings Hold 16
$25.99 Buy/Sell $46.60 -1.89%
MDXG Stock Forecast MiMedx Group Buy 6
$7.45 Buy/Sell $11.85 67.79%
ORGO Stock Forecast Organogenesis Holdings Outperform 10
$3.03 Buy/Sell $4.75 65.02%
RCEL Stock Forecast AVITA Medical Buy 6
$8.26 Buy/Sell $37.39 309.44%

RegenETP Revenue Forecast for 2023 - 2025 - 2030

In the last two years, RegenETP has seen a decline in its Revenue, from $10.13M to $810.00k – a 92.00% decrease. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach $6.56M – an increase of 709.58%. Over the next eight years, experts anticipate that Revenue growth for RegenETP will be 10048.91%.

2023 Rev Forecast
$0.01B
2024 Rev Forecast
$0.03B
2025 Rev Forecast
$0.11B
2026 Rev Forecast
$0.02B
2027 Rev Forecast
$0.04B
2028 Rev Forecast
$0.08B
2029 Rev Forecast
$0.16B
2030 Rev Forecast
$0.08B

RegenETP Dividend per Share Forecast for 2023 - 2025 - 2030

RegenETP Free Cash Flow Forecast for 2023 - 2025 - 2030

RegenETP EBITDA Forecast for 2023 - 2025 - 2030

RegenETP's EBITDA has decreased In the last two years, from $-36.43M to $-24.37M – a 33.10% drop. For next year, the 0 analysts predict EBITDA of $-29.71M, which would mean an increase of 21.91%. Over the next eight years, the pros' prediction is EBITDAof $-30.34M, which would mean a eight-year growth forecast of 24.50%.

2023 EBITDA Forecast
$-29710279.33
2024 EBITDA Forecast
$-32340629.40
2025 EBITDA Forecast
$-31813477.14
2026 EBITDA Forecast
$-29221739.20
2027 EBITDA Forecast
$-29455513.11
2028 EBITDA Forecast
$-30411835.44
2029 EBITDA Forecast
$-30912617.00
2030 EBITDA Forecast
$-30340733.58

RegenETP EBIT Forecast for 2023 - 2025 - 2030

In the last two years, RegenETP's EBIT has seen a drop from $-39.69M to $-25.88M – a 34.79% decrease. In the next year, analysts expect EBIT to reach $-32.16M – an increase of 24.27%. For the next eight years, the forecast is for EBIT to grow by 27.48%.

2023 EBIT Forecast
$-32161938.67
2024 EBIT Forecast
$-35181944.71
2025 EBIT Forecast
$-34831297.99
2026 EBIT Forecast
$-31684870.74
2027 EBIT Forecast
$-31934125.06
2028 EBIT Forecast
$-33015627.43
2029 EBIT Forecast
$-33661633.20
2030 EBIT Forecast
$-32990644.65

RegenETP EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, EPS for RegenETP has grown by 100.00%, going from $-27.03 to $0.00. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $0.00 – an increase of 100.00%. Over the next six years, experts anticipate that EPS growth for RegenETP will be 100.00%.

2025 EPS Forecast
$0.00
2026 EPS Forecast
$0.00
2027 EPS Forecast
$0.00
2028 EPS Forecast
$0.00
2029 EPS Forecast
$0.00
2030 EPS Forecast
$0.00